Aurinia Pharmaceuticals (NASDAQ:AUPH) Share Price Crosses Below 50 Day Moving Average – Here’s Why

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $12.05 and traded as low as $11.39. Aurinia Pharmaceuticals shares last traded at $11.84, with a volume of 1,091,293 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have commented on AUPH shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Royal Bank Of Canada increased their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $13.00.

Aurinia Pharmaceuticals Price Performance

The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The stock has a market cap of $1.56 billion, a P/E ratio of 27.54 and a beta of 1.25. The firm’s fifty day moving average price is $12.05 and its 200-day moving average price is $9.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, Director Kevin Tang purchased 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the purchase, the director directly owned 11,329,500 shares of the company’s stock, valued at $132,328,560. The trade was a 1.80% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders acquired a total of 1,300,000 shares of company stock valued at $13,590,000 over the last ninety days. Company insiders own 12.20% of the company’s stock.

Institutional Trading of Aurinia Pharmaceuticals

A number of hedge funds have recently modified their holdings of AUPH. Nuveen LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth about $10,014,000. Qube Research & Technologies Ltd increased its holdings in Aurinia Pharmaceuticals by 45.1% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,242,512 shares of the biotechnology company’s stock worth $10,524,000 after acquiring an additional 386,364 shares in the last quarter. Jupiter Asset Management Ltd. increased its holdings in Aurinia Pharmaceuticals by 24.1% in the 2nd quarter. Jupiter Asset Management Ltd. now owns 933,862 shares of the biotechnology company’s stock worth $7,910,000 after acquiring an additional 181,093 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Aurinia Pharmaceuticals by 34.1% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 746,229 shares of the biotechnology company’s stock worth $6,000,000 after purchasing an additional 189,775 shares during the period. Finally, Trexquant Investment LP boosted its position in shares of Aurinia Pharmaceuticals by 58.5% during the 1st quarter. Trexquant Investment LP now owns 700,638 shares of the biotechnology company’s stock valued at $5,633,000 after acquiring an additional 258,620 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.